1887

Abstract

The simultaneous use of antifungals with immunosuppressive agents has become a necessity for patients taking immunosuppressive therapy. However, antifungal drugs are problematic because of their limited target.

Scientists have been searching for new antifungals and some compounds with at least additive effects on antifungals. Calcineurin inhibitors used as immunosuppressive agents also attract attention due to their antifungal property.

To evaluate the activity of two calcineurin inhibitors alone and in combination with amphotericin B (AMB), caspofungin (CAS), itraconazole (ITR), voriconazole (VOR) and fluconazole (FLU).

MICs of AMB, CAS, ITR, VOR, FLU and cyclosporine A (CsA) and tacrolimus (TAC) as calcineurin inhibitors were evaluated by the broth microdilution method against (=13), (=7) and (=10). Checkerboard and time-kill methods were performed to investigate the activity of combining calcineurin inhibitors with antifungal drugs.

The lowest MIC values were detected with VOR for all isolates tested. Although we did not detect any inhibition for CsA or TAC alone at concentrations tested in this study, the combinations of CAS with CsA showed the highest synergistic activity (36.7%) by the checkerboard method, and CAS with CsA and ITR with TAC combinations exhibited apparent synergistic interaction by the time-kill method. However, the combinations of both CsA and TAC with AMB resulted in antagonistic interactions, especially against isolate in time-kill testing.

Synergistic interactions in the combinations of TAC or CsA with antifungal drugs, except for AMB, in many concentrations was found to be promising in terms of the treatment of patients with fungal infections.

Funding
This study was supported by the:
  • Türkiye Bilimsel ve Teknolojik Araştirma Kurumu (Award 112S503)
    • Principle Award Recipient: NuriKİRAZ
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001354
2021-04-29
2021-05-15
Loading full text...

Full text loading...

References

  1. Vazquez JA. Combination antifungal therapy against Candida species: the new frontier-are we there yet?. Med Mycol 2003; 41:355–368 [CrossRef]
    [Google Scholar]
  2. Rojas R, Molina JR, Jarque I, Sanz MA, Montes C et al. Outcome of antifungal combination therapy for invasive mold infections in hematological patients is independent of the chosen combination. Mediterr J Hematol Infect Dis 2012; 4:e2012011 [CrossRef]
    [Google Scholar]
  3. Peri AM, Verna M, Biffi S, Alagna L, Longhi B et al. Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: data from a real-life Case-Series. PAI 2019; 4:180–194 [CrossRef]
    [Google Scholar]
  4. Oz Y, Dag I, Kiraz N. Broth microdilution and Time–Kill testing of caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei. Mycopathologia 2012; 173:27–34 [CrossRef]
    [Google Scholar]
  5. Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N et al. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods. Antimicrob Agents Chemother 2010; 54:2244–2247 [CrossRef]
    [Google Scholar]
  6. Butts A, Palmer GE, Rogers PD. Antifungal adjuvants: preserving and extending the antifungal arsenal. Virulence 2017; 8:198–210 [CrossRef]
    [Google Scholar]
  7. Yao L, Wan Z, Li R, Yu J. In Vitro triple combination of antifungal drugs against Clinical Scopulariopsis and Microascus Species. Antimicrob Agents Chemother 2015; 59:5040–5043 [CrossRef][PubMed]
    [Google Scholar]
  8. Chen SC, Lewis RE, Kontoyiannis DP. Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species. Virulence 2011; 2:280–295 [CrossRef]
    [Google Scholar]
  9. Cruz MC, Del Poeta M, Wang P, Wenger R, Zenke G et al. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother 2000; 44:143–149 [CrossRef][PubMed]
    [Google Scholar]
  10. Tome M, Zupan J, Tomičić Z, Matos T, Raspor P. Synergistic and antagonistic effects of immunomodulatory drugs on the action of antifungals against Candida glabrata and Saccharomyces cerevisiae. PeerJ 2018; 6:e4999 [CrossRef]
    [Google Scholar]
  11. Clinical Laboratory Standards Institute (CLSI) Reference Method for Broth Microdilution Antifungal Susceptibility Testing of Yeasts. Fourth Informational Supplement, M27-S4. USA: Wayne; 2012
    [Google Scholar]
  12. Moody J. Synergism testing: broth microdilution checkerboard and macrodilution methods. In Garcia LS. editor Clinical Microbiology Procedures Handbook, ed. ABD: ASM Press; 2016
    [Google Scholar]
  13. Li H, Chen Z, Zhang C, Gao Y, Zhang X et al. Resistance reversal induced by a combination of fluconazole and tacrolimus (FK506) in Candida glabrata. J Med Microbiol 2015; 64:44–52 [CrossRef]
    [Google Scholar]
  14. Lortholary O, Renaudat C, Sitbon K, Desnos-Ollivier M, Bretagne S et al. The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Med 2017; 43:652–662 [CrossRef]
    [Google Scholar]
  15. Koneman GW, Schreckenberger PC, Woods GL. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology, 7th ed. Wolters Kluwer; 2017 p 1830
    [Google Scholar]
  16. Sun S, Li Y, Guo Q, Shi C, Yu J et al. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother 2008; 52:409–417 [CrossRef]
    [Google Scholar]
  17. Zhang J, Heitman J, Chen YL. Comparative analysis of calcineurin signaling between Candida dubliniensis and Candida albicans. Commun Integr Biol 2012; 5:122–126 [CrossRef]
    [Google Scholar]
  18. Zhang M, Yang X, Wang D, Yu C, Sun S. Antifungal activity of immunosuppressants used alone or in combination with fluconazole. J Appl Microbiol 2019; 126:1304–1317 [CrossRef]
    [Google Scholar]
  19. Clinical Laboratory Standards Institute, (CLSI) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard-Third Edition, CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008
    [Google Scholar]
  20. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002; 49:345–351 [CrossRef]
    [Google Scholar]
  21. Synergy OFC. Antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52:1
    [Google Scholar]
  22. Lindberg E, Hammarström H, Ataollahy N, Kondori N. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia. Sci Rep 2019; 9:1–6 [CrossRef]
    [Google Scholar]
  23. Juvvadi PR, Lee SC, Heitman J, Steinbach WJ. Calcineurin in fungal virulence and drug resistance: prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. Virulence 2017; 8:186–197 [CrossRef]
    [Google Scholar]
  24. Robbins N, Caplan T, Cowen LE. Molecular evolution of antifungal drug resistance. Annu Rev Microbiol 2017; 71:753–775 [CrossRef]
    [Google Scholar]
  25. Cowen LE, Steinbach WJ. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 2008; 7:747–764 [CrossRef]
    [Google Scholar]
  26. Steinbach WJ, Cramer RA, Perfect BZ, Asfaw YG, Sauer TC et al. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell 2006; 5:1091–1103 [CrossRef]
    [Google Scholar]
  27. Borba-Santos LP, Reis de Sá LF, Ramos JA, Rodrigues AM, de Camargo ZP. Tacrolimus increases the effectiveness of itraconazole and fluconazole against Sporothrix spp. Frontiers in Microbiolog 1759; 2017:8
    [Google Scholar]
  28. Steinbach WJ, Reedy JL, Cramer RA, Perfect JR, Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 2007; 5:418–430 [CrossRef]
    [Google Scholar]
  29. Badiee P, Badali H, Boekhout T, Diba K, Moghadam AG et al. Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates. BMC Infect Dis 2017; 17:1–8 [CrossRef]
    [Google Scholar]
  30. Wong SSW, Rasid O, Laskaris P, Fekkar A, Cavaillon JM et al. Treatment of cyclosporin A retains host defense against invasive pulmonary aspergillosis in a non-immunosuppressive murine model by preserving the myeloid cell population. Virulence 2017; 8:1744–1752 [CrossRef]
    [Google Scholar]
  31. High KP. The antimicrobial activities of cyclosporine, FK506, and rapamycin. Transplantation 1994; 57:1689–1700 [CrossRef]
    [Google Scholar]
  32. Sepaskhah M, Sadat MS, Pakshir K, Bagheri Z. Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: a single blind, randomised clinical trial. Mycoses 2017; 60:338–342 [CrossRef]
    [Google Scholar]
  33. Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008; 52:1127–1132 [CrossRef]
    [Google Scholar]
  34. Denardi LB, Mario DA, Loreto Érico Silva, Santurio JM, Alves SH. Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates. Braz J Microbiol 2015; 46:125–129 [CrossRef][PubMed]
    [Google Scholar]
  35. Gao L, Sun Y. In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. Antimicrob Agents Chemother 2015; 59:7097–7099 [CrossRef]
    [Google Scholar]
  36. Jia W, Zhang H, Li C, Li G, Liu X et al. The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms. BMC Microbiol 2016; 16:113 [CrossRef]
    [Google Scholar]
  37. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP et al. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother 2000; 44:2932–2938 [CrossRef]
    [Google Scholar]
  38. Onyewu C, Blankenship JR, Del Poeta M, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 2003; 47:956–964 [CrossRef][PubMed]
    [Google Scholar]
  39. Onyewu C, Afshari NA, Heitman J. Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. Antimicrob Agents Chemother 2006; 50:3963–3965 [CrossRef]
    [Google Scholar]
  40. Li Y, Sun S, Guo Q, Ma L, Shi C et al. In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J Antimicrob Chemother 2008; 61:577–585 [CrossRef]
    [Google Scholar]
  41. Cordeiro RdeA, Macedo RdeB, Teixeira CEC, Marques FJdeF, Bandeira TdeJPG et al. The calcineurin inhibitor cyclosporin A exhibits synergism with antifungals against Candida parapsilosis species complex. J Med Microbiol 2014; 63:936–944 [CrossRef][PubMed]
    [Google Scholar]
  42. Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008; 52:735–738 [CrossRef][PubMed]
    [Google Scholar]
  43. Kubiça TF, Denardi LB, Azevedo MI, Oliveira V, Severo LC et al. Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates. Braz J Infect Dis 2016; 20:539–545 [CrossRef]
    [Google Scholar]
  44. Butts A, Reitler P, Ge W, Fortwendel JR, Palmer GE. Commonly used oncology drugs decrease antifungal effectiveness against Candida and Aspergillus species. Antimicrob Agents Chemother 2018; 62:e00504–00518 [CrossRef]
    [Google Scholar]
  45. Spader TB, Ramírez-Castrillón M, Valente P, Alves SH, Severo LC. In vitro interactions of amphotericin B combined with Non-antifungal Agents against Rhodotorula mucilaginosa strains. Mycopathologia 2019; 184:35–43 [CrossRef][PubMed]
    [Google Scholar]
  46. Tripathi SK, Feng Q, Liu L, Levin DE, Roy KK et al. Puupehenone, a marine-sponge-derived sesquiterpene quinone, potentiates the antifungal drug caspofungin by disrupting Hsp90 activity and the cell wall integrity pathway. mSphere 2020; 5:e00818–00819 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001354
Loading
/content/journal/jmm/10.1099/jmm.0.001354
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error